Classification

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Retrieved on: 
Friday, April 5, 2024
IOV, Tao, Medicine, Savolitinib, VEGFR, Immunotherapy, Patient, MMAE, ERK, Relapse, Neoplasm, University, Huachung University, Cisplatin, Lymphoid leukemia, Lymphoma, Chongqing Medical University, Cholangiocarcinoma, Tyrosine-protein kinase SYK, Classification, Efficacy, MET, ADC, Cardiotoxicity, Nanjing Medical University, Non-receptor tyrosine kinase, Safety, Ferroptosis, Macrophage, Pancreatic cancer, Dual role, National Taiwan University Hospital, GPR34, Oncology, Guangzhou Medical University, MD Anderson Cancer Center, Daratumumab, HCM, NPM1, MLL, 301 Hospital, Acute leukemia, Pharmaceutical industry

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.
  • Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia.
  • Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models.
  • Furthermore, HMPL-506 in combination with azacytidine, venetoclax or gilteritinib synergistically improved the anti-tumor effect against MLL-rearranged leukemias both in vitro and in vivo.

Lithium Ionic Announces Maiden Mineral Resource Estimate and Initiation of PEA at its Salinas Project, Minas Gerais, Brazil; Increases Regional Mineral Resources by 45%

Retrieved on: 
Thursday, April 4, 2024
Lithium, Diamond, QA/QC, Environmental impact assessment, SNC-Lavalin, Environment, CAPEX, Classification, Mineral Resources Limited, Project, MRE, Feasibility study, QP, Risk, PEA, Mining, EIA, Pit, Marketing, Sustainable development, Bandeira, Uranium mining

TORONTO, April 04, 2024 (GLOBE NEWSWIRE) --  Lithium Ionic Corp. (TSXV: LTH; OTCQX: LTHCF; FSE: H3N) (“Lithium Ionic” or the “Company”), is pleased to announce an initial NI 43-101 compliant Mineral Resource Estimate (“MRE”) for its Salinas Lithium Project (“Salinas” or the “Project”), increasing its global mineral resources by 45%. The Salinas property covers 662 hectares or ~4.5% of Lithium Ionic’s large 14,182-hectare land package within the “Lithium Valley” in Minas Gerais State, Brazil, and represents the third NI 43-101 compliant lithium MRE the Company has established to date. The “Lithium Valley” is a unique geological belt that hosts a significant concentration of lithium-bearing pegmatites, which are among the largest and highest grade in the world. The Company’s properties are located in a district that is quickly emerging as an important global lithium producer.

Key Points: 
  • Independent Brazilian consultancy, GE21 Consultoria Mineral Ltda , based in Belo Horizonte, Minas Gerais, has been engaged to carry out a PEA based on the Salinas MRE.
  • Data from a total of 122 drill holes comprising 3,276 assays were included in the mineral resources model.
  • The 3D modelling of lithium Mineral Resources was conducted using a minimum cut-off grade of 0.3% Li2O within a preliminary lithological model.
  • The MRE was classified as Measured, Indicated and Inferred Mineral Resource based on data quality, sample spacing, and pegmatite continuity.

NatureServe Expands Access to Critical Biodiversity Data with the Launch of NatureServe Explorer Pro

Retrieved on: 
Thursday, April 4, 2024
CIO, Science, Exploration, Research, Classification, Biodiversity, NatureServe, Interim, Animal

The advanced platform provides users with unparalleled access to detailed information on at-risk species, reinforcing NatureServe's commitment to conserving biodiversity as the go-to source for decision-quality biodiversity data.

Key Points: 
  • The advanced platform provides users with unparalleled access to detailed information on at-risk species, reinforcing NatureServe's commitment to conserving biodiversity as the go-to source for decision-quality biodiversity data.
  • NatureServe Explorer Pro offers users high-quality biodiversity information for data-driven conservation planning and environmental screening.
  • “NatureServe Explorer Pro is a critical open data platform for discovery, exploration, and dissemination of biodiversity data,” said Patrick Henry, Executive Director of NatureServe Canada.
  • “With powerful mapping tools and detailed data, NatureServe Explorer Pro expands our capacity to deliver high-quality scientific information,” said Lori Scott, Interim CEO and CIO of NatureServe.

Sophos Partners with Tenable to Launch New Sophos Managed Risk Service

Retrieved on: 
Wednesday, April 3, 2024
MSSP, Organization, Phoenix Technologies, Partnership, Risk, Classification, IDC, Software, MDR, Security, API, MSP, Workload, Remote Desktop Protocol, Managed services, RDP, Risk management

OXFORD, United Kingdom, April 03, 2024 (GLOBE NEWSWIRE) -- Sophos, a global leader of innovative security solutions that defeat cyberattacks, today announced a strategic partnership with Tenable®, the Exposure Management company, to provide Sophos Managed Risk, a worldwide vulnerability and attack surface management service. The new service features a dedicated Sophos team that leverages Tenable's exposure management technology and collaborates with the security operations experts from Sophos Managed Detection and Response (MDR) to provide attack surface visibility, continuous risk monitoring, vulnerability prioritization, investigation, and proactive notification designed to prevent cyberattacks.

Key Points: 
  • “Sophos and Tenable are two industry security leaders coming together to address urgent, pervasive security challenges that organizations continuously struggle to control.
  • “Solutions such as Sophos Managed Risk can be a differentiator by enabling overwhelmed teams to take a more holistic approach to continuous monitoring and threat management.”
    Sophos Managed Risk is available as an extended service with Sophos MDR, which already protects more than 21,000 organizations globally.
  • The Sophos Managed Risk team is Tenable-certified and works closely with Sophos MDR to share essential information about zero-days, known vulnerabilities and exposure risks to assess and investigate possibly exploited environments.
  • Sophos Managed Risk is shining a light on areas of exposure that require remediation in order to keep customers protected.

Envoy Medical Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, April 2, 2024
House, Growth, Congress, Patient, COCH, EFS, Classification, Hope, Esteem, Business analyst, Insurance, Kool-Aid, Clinical trial, Patent, Medicare, Marketing, CMS, Hearing, Representative

WHITE BEAR LAKE, Minn., April 02, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Completed Business Combination transaction at the end of September and began trading on Nasdaq under its own ticker, COCH, the first week of October 2023.
  • Early Feasibility Study (EFS) continues to meet milestones with all three implanted patients surpassing twelve-month post-activation visits remaining implanted.
  • Sales and marketing expenses increased $0.8 million for the year ended December 31, 2023 compared to the same period in 2022.
  • The increase is primarily due to a $2.8 million rise in professional and legal fees in 2023 related to the finalization of the Business Combination in the third quarter of 2023.

Bionano Announces 9 Poster Presentations and Introduces New High Throughput Stratys™ System at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Tuesday, April 2, 2024
SAN, NGS, Research, Classification, Cancer, Software, AACR, Genomics, VAF, Bone marrow, OGM, VIA, Medicine, Medical imaging

AACR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in cancer science and medicine.

Key Points: 
  • AACR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in cancer science and medicine.
  • The AACR conference will be held April 5-10, 2024, in San Diego, California.
  • Bionano will introduce its new Stratys™ system, which offers higher throughput and improved sample flexibility, to the cancer research community at the conference.
  • Nine scientific poster presentations will illustrate OGM’s utility for cancer research in areas including solid tumors, hematological malignancies, as well as applications in cell and gene therapy and cell manufacturing and bioprocessing quality control.

Acutus Medical Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, April 1, 2024
AFIB, Research, Classification, Sale, Electrophysiology, Medtronic, 2012 Six-red World Championship, GAAP, Operation, Marketing, Video game

CARLSBAD, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the fourth quarter and full year ended December 31,2023.

Key Points: 
  • CARLSBAD, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the fourth quarter and full year ended December 31,2023.
  • Announced strategic realignment of resources and corporate restructuring on November 8, 2023 with the objective of optimizing financial position and maximizing free cash flow.
  • Fourth quarter revenue from Continuing Operations of $2.4 million grew 118% year-over-year, from $1.1 million in the year ago fourth quarter.
  • Revenue from Continuing Operations was $2.4 million for the fourth quarter of 2023, an increase of 118% compared to $1.1 million for the fourth quarter of 2022.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of PSQ Holdings, Inc. - PSQH

Retrieved on: 
Sunday, March 31, 2024
Classification, News, LLP, WalletHub, Security (finance), Business analyst, Bank statement, ASC, Pomerantz, PSQ

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PSQ Holdings, Inc. (“PSQ” or the “Company”) (NYSE: PSQH).Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Key Points: 
  • NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PSQ Holdings, Inc. (“PSQ” or the “Company”) (NYSE: PSQH).Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
  • The investigation concerns whether PSQ and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Descartes Acquires OCR

Retrieved on: 
Thursday, March 28, 2024
DSG, Descartes Systems Group, Classification, Artificial intelligence, SAP, OCR, TSX, Commerce, Visual Compliance, Hand

WATERLOO, Ontario and ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Descartes Systems Group (TSX:DSG) (Nasdaq:DSGX), the global leader in uniting logistics-intensive businesses in commerce, announced that it has acquired OCR Services, Inc. (“OCR”), a leading provider of global trade compliance solutions and content.

Key Points: 
  • WATERLOO, Ontario and ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Descartes Systems Group (TSX:DSG) (Nasdaq:DSGX), the global leader in uniting logistics-intensive businesses in commerce, announced that it has acquired OCR Services, Inc. (“OCR”), a leading provider of global trade compliance solutions and content.
  • Similar to Descartes, OCR monitors regulatory sources and updates their trade data content libraries daily.
  • “The OCR team brings a wealth of domain expertise in global trade compliance to Descartes, including experience leveraging artificial intelligence (AI) in the content management process,” said Andrew Roszko, Chief Commercial Officer at Descartes.
  • We’re thrilled to welcome the OCR employees, customers and partners into the Descartes family.”
    OCR is headquartered in Rockville, Maryland.

Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Wednesday, March 27, 2024
De novo, DFU, Diabetic foot ulcer, Certification, Burn, Government, Development, FY, MDAI, Patient, Research, History, Artificial intelligence, Classification, Sale, Standard of care, Human services, Research and development, Wound healing, Trial of the century, Clinical trial, ASPR, ISO, FDA, Administration, Food, Pharmaceutical industry

DALLAS, March 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2023”) and full year (“FY 2023”) ended December 31, 2023 and provided an update on its ongoing business activities.

Key Points: 
  • DALLAS, March 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2023”) and full year (“FY 2023”) ended December 31, 2023 and provided an update on its ongoing business activities.
  • “Spectral AI achieved much in 2023, and our progress along multiple fronts has continued into 2024,” said Peter M. Carlson, Chief Executive Officer.
  • “
    In September 2023, we were awarded the largest contract in our history from the US Government valued at up to $150.0 million.
  • All comparisons to Q4 2023 and FY 2023 are to the comparable periods ended December 31, 2022, unless otherwise stated.